Kintor’s GT20029 Phase 1 success
    Update 12/5/2022

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💧 GT20029 (topical) infrequent
    💧 Pyrilutamide (topical) 6 months
    💧 Finasteride (topical) microdosed
    💧 Minoxidil (topical)
    💧 RU58841 (topical) 6 months
    the tone is 😀 positive.

    Other terms

    Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
    View this post in the Community →

    Similar Community Posts Join

    5 / 256 results

      community 1 month Pyrilutamide. A non responders story to everything.

      in Research/Science  218 upvotes 2 years ago
      My hairline, I am only 23. This conversation is about a user's experience with treatments for androgenic alopecia, including finasteride, dutasteride, RU, minoxidil, progesterone, melatonin, LLLT, oral minoxidil, and Pyrilutamide. They have tried many treatments over the course of two years without seeing much success, and they are considering getting a hair system as a last resort.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 11 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  125 upvotes 1 year ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community A concern regarding the upcoming androgen degrader drug GT20029

      in Chat  10 upvotes 2 months ago
      GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

      community It’s over. NOTHING has worked.

      in Chat  95 upvotes 2 years ago
      A user who has been trying various treatments for hair loss for four years, with no success. Suggestions include use of minoxidil, finasteride, RU58841, microneedling, supplements and multivitamins, lifestyle changes, scalp biopsy, and SMP.

    Related Research

    6 / 7 results